Solvias and RohnerChem announced a partnership for custom research and manufacturing services. The preferred but non-exclusive partnership closes the chain of services from route scouting through to commercial manufacturing. Customers will benefit from the synergy of Solvias’ expertise in chemical, analytical and solid-state development and RohnerChem’s experience in scale-up and commercial scale custom synthesis of complex, small molecule fine chemicals and APIs.
Solvias applies high throughput screening methods (HTS) which have been used successfully in asymmetric homogeneous catalysis, CX-couplings, racemate resolutions, carbonylations, hydroformylations, biocatalysis development, and various other transformations. Solvias’ solid-state development group is also fully equipped to assist in developing crystallization processes, perform polymorphism studies and provide guidance in the development of the best solid form for any API. After process optimization, which can be performed either at Solvias’ or at RohnerChem’s Kilolab, commercial quantities can be manufactured at RohnerChem’s FDA inspected facilities. The cooperation will ensure consideration of upscaling requirements from early phases onwards, resulting in reduced overall timelines.
Both companies will continue to capitalize on their strong expertise in the area of enantioselective catalysis for the efficient production of building blocks and APIs and from the ideal fit of key technologies in catalytic, high-pressure, organometallic, cryogenic and various other technology areas.
Financial terms of the partnership were not disclosed.